Previous 10 | Next 10 |
2024-03-28 07:38:20 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- Avalo Therapeutics, Inc. (NASDAQ: AVTX ) reported, after yesterday’s market close, that it acquired AlmataBio, Inc. and its Phase 2-ready anti-IL-1β mAb. Additionally, Avalo agreed to sell pr...
2024-03-27 16:16:07 ET More on Avalo Therapeutics Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics Read the full article on Seeking Alpha For further...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront invest...
2023-12-29 13:02:59 ET Gainers: Sentage Holdings ( SNTG ) +262% . China SXT Pharmaceuticals ( SXTC ) +107% . China Green Agriculture ( CGA ) +54% . Aditxt ( ADTX ) +33% . TC BioPharm ( TCBP ) +30% . Bright Health Group ( BH...
2023-12-29 08:02:08 ET Avalo Therapeutics Inc (AVTX) announced stock split at a ratio of 1-for-239.808 on 2023-12-29 ... Full story available on KlickAnalytics.com
2023-12-27 07:29:39 ET More on Avalo Therapeutics Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics For further details see: Avalo Therapeutics announces ...
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’...
Annual Meeting has been adjourned until December 20, 2023 Most stockholders can vote via proxyvote.com or by calling 1-800-690-6903. If you have any questions about how to vote, please call 1-800-607-0088 WAYNE, Pa. and ROCKVILLE, Md., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Avalo Thera...
2023-11-09 07:46:12 ET More on Avalo Therapeutics Avalo enters agreement to divest AVTX-800 series Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics F...
Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assets Disclosed improved cash of approximately $10.2 mil...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...